Drug Type Bispecific antibody |
Synonyms MT 6194, MT6194 |
Target |
Action inhibitors, antagonists |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors), Interleukin-6 receptor antagonists |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Autoimmune Diseases | Preclinical | United States | 18 Sep 2017 | |
Inflammation | Preclinical | United States | 18 Sep 2017 |